<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Bioinformation</journal-id><journal-id journal-id-type="iso-abbrev">Bioinformation</journal-id><journal-id journal-id-type="publisher-id">Bioinformation</journal-id><journal-title-group><journal-title>Bioinformation</journal-title></journal-title-group><issn pub-type="ppub">0973-8894</issn><issn pub-type="epub">0973-2063</issn><publisher><publisher-name>Biomedical Informatics</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400663</article-id><article-id pub-id-type="pmc">PMC12093257</article-id><article-id pub-id-type="publisher-id">973206300200404</article-id><article-id pub-id-type="doi">10.6026/973206300200404</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Screening of Leptin-LepR modulators using molecular docking and binding assay</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jim&#x000e9;nez-Pineda</surname><given-names>Albertana</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="COR3" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Vique-S&#x000e1;nchez</surname><given-names>Jos&#x000e9; Luis</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="COR4" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Medina-Contreras</surname><given-names>Oscar</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Benitez-Cardoza</surname><given-names>Claudia G</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="COR2" ref-type="corresp">*</xref></contrib><aff id="A1"><label>1</label>Laboratorio de Investigaci&#x000f3;n Bioqu&#x000ed;mica y Biof&#x000ed;sica Computacional, ENMyH, Instituto Polit&#x000e9;cnico Nacional, Guillermo Massieu Helguera, No. 239, Fracc. "La Escalera", Ticom&#x000e1;n, C.P. 07320, Ciudad de M&#x000e9;xico, M&#x000e9;xico</aff><aff id="A2"><label>2</label>Facultad de Medicina Mexicali, Universidad Aut&#x000f3;noma de Baja California, CP 02100, BC, M&#x000e9;xico</aff><aff id="A3"><label>3</label>Unidad de Investigaci&#x000f3;n Epidemiol&#x000f3;gica en Endocrinolog&#x000ed;a y Nutrici&#x000f3;n, Hospital Infantil de M&#x000e9;xico Federico G&#x000f3;mez, CP 06720, Ciudad de M&#x000e9;xico</aff></contrib-group><author-notes><corresp id="COR1"><label>1</label>Oscar Medina-Contreras <email>omedina@himfg.edu.mx</email></corresp><corresp id="COR2"><label>2</label>Claudia G. Benitez-Cardoza <email>cbenitezc@ipn.mx</email></corresp><corresp id="COR3"><label>3</label>Albertana Jim&#x000e9;nez-Pineda <email>ajimenezp1601@alumno.ipn.mx</email></corresp><corresp id="COR4"><label>4</label>Jos&#x000e9; Luis Vique-S&#x000e1;nchez <email>jvique@uabc.edu.mx</email></corresp></author-notes><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>31</day><month>5</month><year>2024</year></pub-date><volume>20</volume><issue>5</issue><fpage>404</fpage><lpage>411</lpage><history><date date-type="received"><day>1</day><month>5</month><year>2024</year></date><date date-type="rev-recd"><day>31</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>31</day><month>5</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 Biomedical Informatics</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/3.0/</ali:license_ref><license-p>This is an Open Access article which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.</license-p></license></permissions><abstract><p>Leptin is a pleiotropic hormone which, upon binding to its cognate leptin receptor (LepR), induces the activation of the JAK2/ERK,
STAT3/STAT5 and IRS/PI3 kinase signaling cascades. Hence, we used molecular docking and a chemical library to identify 18 compounds with
high probability of interacting with the leptin binding domain (LBD) of LepR. 6 out of 18 compounds were selected based on toxicological
and physicochemical properties to evaluate their effect in the formation of Leptin-LepR complex using ELISA assays. The six compounds
showed discreet but significant modulation on the complex formation. These results have important implications in proposing novel
strategies for modulating the formation of the Leptin-LepR complex, as therapeutic alternatives for patho-physiologies where the
formation of this complex is deregulated.</p></abstract><kwd-group><kwd>Leptin receptor</kwd><kwd>drug-like compounds</kwd><kwd>protein-compound docking</kwd><kwd>interactions</kwd><kwd>ADMET properties</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Background:</title><p>The maintenance of homeostasis and the regulation of growth are essential physiological processes requiring precise control mechanisms.
Among these mechanisms, the leptin-leptin receptor (LepR) axis plays a critical role in a wide array of physiological functions. Leptin,
classified as a class I cytokine and its receptor, LepR, exert their influence on diverse processes. Leptin modulates food intake and
energy expenditure by acting on anorexigenic pathways within the hypothalamus and regulating metabolism and energy homeostasis in
peripheral tissues [<xref rid="R01" ref-type="bibr">1</xref>]. Additionally, the leptin-LepR axis participates in glucose homeostasis,
reproductive functions, bone formation and wound healing processes. Leptin plays a significant role in both innate and adaptive
immunity. Leptin controls the activation and function of macrophages, neutrophils, monocytes, dendritic cells and natural killer cells.
Additionally, it promotes the production of pro-inflammatory cytokines. Also, leptin influences thymic and splenic homeostasis, promotes
the proliferation of naive CD4+ T cells and skews T helper cell differentiation towards TH1 and TH17 responses while suppressing
regulatory T cells [<xref rid="R02" ref-type="bibr">2</xref>]. Due to its involvement in immune system modulation, the leptin-LepR axis
has been implicated in the development and progression of several autoimmune diseases, including multiple sclerosis, antigen-induced
arthritis, hepatitis, colitis and glomerulonephritis. This link is further supported by evidence from animal models, where
leptin-deficient rodents exhibit protection against these autoimmune conditions, while leptin administration restores disease
susceptibility [<xref rid="R03" ref-type="bibr">3</xref>, <xref rid="R04" ref-type="bibr">4</xref>]. Other evidence of the importance of
the leptin/LepR axis in pathologies are the reports of higher expression levels of both leptin and its receptors in various types of
cancer, such as prostate and breast cancer; specifically in breast cancer these increases have been significantly related to distant
metastasis, other types of cancer where overexpression of leptin and leptin receptors has been observed is endometrial cancer and
gastric cancer [<xref rid="R05" ref-type="bibr">5</xref>]. Six isoforms of LepR, generated by alternative splicing, have been described.
These isoforms are classified into short (LepRa, LepRc, LepRd, LepRf) long (LepRb) and secreted (LepRe). All of them share the
extracellular leptin-binding domain (LBD) of 816 amino acids, a transmembrane domain of 34 amino acids (except the soluble isoform). The
cytoplasmic domains are different in each of the isoforms. The extracellular region is divided into six domains: an N-terminal domain
(NTD), two CRH domains (CRH1 and CRH2), an immunoglobulin-like domain (IGD) and two additional fibronectin type III domains near the
membrane (FN III) [<xref rid="R06" ref-type="bibr">6</xref>]. It has been described that LepR activation requires the CRH2, IGD and FN
III domains. Only the CRH2 domain is strictly required for leptin binding to its receptor. This was demonstrated by measuring the KD of
leptin binding to this domain, which was comparable to the KD of leptin binding to the entire extracellular domain of LepR. For this
reason, this domain is commonly known as the leptin-binding domain. Through a detailed mutagenesis exploration of the CRH2 domain to
determine the leptin/LepR interaction, the importance of five hydrophobic residues (503-IFLL-506, Y472) located in this domain has been
evidenced; mutations of these residues lead to a decrease of leptin binding and decreased signaling [<xref rid="R07" ref-type="bibr">7</xref>].
Genetic evidence has indicated that the biological effects of leptin are primarily the result of binding to LepRb, which is the only splice
variant of the leptin receptor that harbors all the residues necessary for signal transduction. LepRb is mainly expressed in the brain
and in hematopoietic and immune cells. It has also been found highly expressed in the intestine, while the other splice variants show a
wide distribution in tissues including kidney, ovary, uterus, testis, liver, lung, adrenal gland and spleen. The extensive expression of
leptin receptor isoforms at the functional level denotes the pleiotropic effects of leptin [<xref rid="R02" ref-type="bibr">2</xref>].
Therefore, it is of interest to describe the screening of Leptin-LepR modulators using molecular docking and binding assay.</p></sec><sec id="s2"><title>Materials and Methods:</title></sec><sec id="s2a"><title>Leptin receptor model:</title><p>The three-dimensional model of the leptin-binding domain (CRH2, residues 431 to 634) of the human leptin receptor (UniProt: P48357),
was built using the I-TASSER server, as described by L&#x000f3;pez-Hidalgo <italic>et al.</italic> [<xref rid="R08" ref-type="bibr">8</xref>].
Upon validation, the model was subjected to molecular dynamics simulations for 100 ns at 310 K using the high-performance program GROMACS
[<xref rid="R09" ref-type="bibr">9</xref>]. The conformations were grouped in clusters according to their root-mean-square deviation of
C-alpha-atomic positions values. The average conformation corresponding to the most populated cluster was used as the 3-D model in this
work.</p></sec><sec id="s2b"><title>Screening library:</title><p>For molecular coupling, the EXPRESS-pick collection stock of the Chembridge Corp. small molecule selection library was used
[<xref rid="R10" ref-type="bibr">10</xref>]. The compounds of this library (Figure 1a, b, c - see PDF) fulfill the pharmacological
properties of Lipinski's rules [<xref rid="R11" ref-type="bibr">11</xref>].</p></sec><sec id="s2c"><title>Molecular docking:</title><p>Molecular Operating Environment (MOE) software was used for coupling, protonation and energy minimization of the PDB file with the
default parameters (Placement: Triangle Matcher, rescoring 1: London &#x00394;G, Refinement: Force field, rescoring 2: London &#x00394;G,
for all compounds were generated and stored 30 conformations) and the CHARMM27 force field [<xref rid="R12" ref-type="bibr">12</xref>].
During docking, the receptor remained rigid, while the ligand atoms were released to move to a maximum number of rotating bonds. All
crystallographic water molecules were removed from the initial structure. The docking was site directed by selecting the region of
interaction with leptin in LBD Y472, I503, F504, L505 y L506 [<xref rid="R13" ref-type="bibr">13</xref>].</p></sec><sec id="s2d"><title>Free binding energy (&#x00394;G<sub>binding</sub>):</title><p>The binding affinity of each complex (ligand-protein) was calculated, with the enthalpic contribution to the free energy of binding
using a linear function using MOE [<xref rid="R14" ref-type="bibr">14</xref>]. The non-bonded interaction energies between the ligand
and protein molecule involve Coulomb electrostatic interactions, Van der Waals and implied solvent interaction energies.</p></sec><sec id="s2e"><title>Selection of compounds:</title><p>18 compounds were selected using the results of up to 30 conformers of each compound for selection. The value calculated for the free
energy of binding (&#x00394;G<sub>binding</sub>) of each complex (Ligand-Protein) was considered as a selection criterion, as reported
[<xref rid="R02" ref-type="bibr">2</xref>, <xref rid="R05" ref-type="bibr">5</xref>]. With these results, the best &#x00394;G<sub>binding</sub>
averages were determined, as well as the standard deviation of each compound using the Excel software.</p></sec><sec id="s2f"><title>Pharmacokinetic properties of compounds:</title><p>Description of chemical properties, hard-boiled egg and theoretical toxicity (carcinogenicity and mutagenicity) were calculated using
SwissADME [<xref rid="R15" ref-type="bibr">15</xref>], admetSAR [<xref rid="R16" ref-type="bibr">16</xref>] and ADMETlab
[<xref rid="R17" ref-type="bibr">17</xref>] and ProTox-II [<xref rid="R18" ref-type="bibr">18</xref>] web servers. For all calculations,
the SMILES chain (Simplified Molecular-Input Line-Entry System) of each compound was inserted in every server.</p></sec><sec id="s2g"><title>Bioactive Leptin ELISA assay:</title><p>Six compounds were tested to evaluate their intervention in the binding of leptin to the leptin receptor. Leptin W100E (obtained as
described by Chimal-Vega <italic>et al.</italic> [<xref rid="R19" ref-type="bibr">19</xref>] and compounds A8, A9, A10, A11, A14 and A17
were used with the Bioactive Leptin ELISA kit from ALPCO, Catalog Number: 22-BLEPHU-E01, Version: 19.12.2022 Revision 003 - ALPCO 1.0,
following the manufacturer's instructions. Before the assay, the corresponding wells of the plate were incubated for 2 hours with 1 mM
of each compound, at room temperature and constant stirring at 350 rpm.</p></sec><sec id="s3"><title>Results:</title></sec><sec id="s3a"><title>Selection of compounds using docking:</title><p>The binding site considered in this work, involves residues Y472, I503, F504, L505 and L506 of LBD-LepR, which have been reported as
the most important site leptin. The 18 top poses, out of almost 500,000 compounds from Chembridge library, were selected, according to
were the lowest &#x00394;G<sub>binding</sub> values (average of the &#x00394;G<sub>binding</sub> corresponding to 30 conformers per
compound), as well as the standard deviation. The selected compounds were named, for convenience; with arbitrarily generated
identification codes with letter A and a consecutive number (A1-A18). <xref rid="T1" ref-type="table">Table 1</xref>, shows the
identification numbers of each compound, the calculated binding scores, the residues within LBD-LepR that interact with each molecule,
as well as some physicochemical properties.</p></sec><sec id="s3b"><title>Physicochemical properties of the compounds:</title><p><xref rid="T1" ref-type="table">Table 1</xref> presents the chemical names, smile code and some physicochemical properties of the
selected compounds. Physicochemical properties, like lipophilia (WLogP), solubility (LogS) and polarity (tPSA; &#x000c5;<sup>2</sup>), among others
are determinant of the pharmacokinetic and pharmacodynamic processes, as well as the safety of the drugs
[<xref rid="R20" ref-type="bibr">20</xref>].</p></sec><sec id="s3c"><title>Pharmacokinetics and pharmacodynamics:</title><p>Further analyses of the 18 selected compounds were carried out to describe their pharmacokinetic and pharmacodynamic processes, using
three website servers; SwissADME, admetSAR and ADMETlab, described in <xref rid="T2" ref-type="table">Table 2</xref>. Gastrointestinal
absorption and access to the brain are two crucial behaviors for estimating at various stages of drug discovery processes. Considering
the relationship between WLogP and tPSA values it is possible to accurately predict the passive human gastrointestinal absorption (HIA)
and blood-brain barrier (BBB) permeability (<xref rid="T1" ref-type="table">Table 1</xref>, Figure 2a - see PDF). According to this model
3 out of the 18 molecules (A3, A13 and A16) might not be well absorbed by these pathways while four molecules are permeable through the
blood-brain barrier (A8, A9, A10 and A11).</p><p>When evaluating the Distribution, two values were considered: the probability of each compound as substrate of permeability
glycoprotein (P-gp) and the percentage of plasma protein binding (PPB). Five out of 18 compounds (A5, A8, A9, A10 and A11) might be P-pg
substrate and four compounds showed PPB percentage equal to or greater than 90% (A6, A12, A16 and A17) (<xref rid="T2" ref-type="table">Table 2</xref>).
P-gp belongs to the ABC superfamily of transporters and is also known as multidrug resistance protein (MDR). P-gp alters drug absorption
(<italic>e.g.</italic>, by expelling drug molecules back into the gastrointestinal lumen in oral drug administration), distribution
(<italic>e.g.</italic>, by preventing drug penetration into the brain), metabolism (<italic>e.g.</italic>, acting synergistically with
cytochrome P450 3A) and excretion (<italic>e.g.</italic>, by affecting the functions of the biliary and renal tubules)
[<xref rid="R21" ref-type="bibr">21</xref>]. This suggests that compounds A5, A8, A9, A10 and A11 that are predicted as substrates of
P-gp may exhibit poor bioavailability by impeding their permeability through physiological barriers.</p><p>Another factor which significantly influences the distribution and elimination of drugs is plasma protein binding. A percentage of
the circulating drug can bind with various affinities to blood proteins and according to the hypothesis of the free drug, only the free
drug is available to act at physiological sites of action; serum albumin, lipoproteins and acid glycoprotein alpha-1 (AAG) are the main
plasma proteins involved in sequestration [<xref rid="R22" ref-type="bibr">22</xref>]. The 18 compounds evaluated are predicted with
more than 50% plasma protein binding (<xref rid="T2" ref-type="table">Table 2</xref>) and particularly, compounds A6, A12, A16 and A17
are predicted with less than 10% as a free fraction. However, 45% of FDA-approved drugs are classified as highly bound (&#x0003e;95% PPB)
[<xref rid="R23" ref-type="bibr">23</xref>] so it is likely that our compounds under physiological conditions may have a biological
effect.</p><p>The possible interaction of drugs with isoenzymes of the cytochrome superfamily P450 (CYP) is fundamental to determine their
metabolism. Therefore, the possible inhibition of the five main isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) was evaluated, in
none of the cases is a single molecule expected to be an inhibitor of these five isoforms (<xref rid="T2" ref-type="table">Table 2</xref>).
The excretion of the compounds was addressed with the prediction of the half-life (T1/2) and the renal clearance (CL). All the poses
showed low range values for both T1/2 and CL (<xref rid="T2" ref-type="table">Table 2</xref>).</p></sec><sec id="s3d"><title>Toxicological properties:</title><p>The toxicological safety of the compounds, analyzed by the PROTOX II server is shown in Figure 2b. The heat map shows prediction of
hepatotoxicity, where 3 of the compounds are predicted with moderate risk (A2, A3 and A16), while in carcinogenicity
(Figure 2b - see PDF) the compounds A1, A2, A16 and A17 are likely at risk. Another important aspect that we considered was
immunogenicity where for 6 of the 18 cases we found irrigation (Figure 2b - see PDF); as for the mutagenicity parameter, the server found
risk in 5 molecules (Figure 2b - see PDF). It is interesting to note that for none of the structures evaluated is predicted risk of
cytotoxicity (Figure 2b - see PDF). In addition, the mean lethal dose (LD50) and the classification of the compounds into toxicity
classes, defined according to the globally harmonized system of chemical labeling classification (GHS) [<xref rid="R24" ref-type="bibr">24</xref>]
are shown in <xref rid="T2" ref-type="table">Table 2</xref>. Three compounds lie in category 3 (A1, A13 and A17) with LD50 &#x0003e;50 mg/kg
&#x02264;300, only the A14 compound is classified in category 5 with an LD50 &#x0003e;5000 mg/kg and the rest of the compounds were classified in
category 4 (LD50 &#x0003e;300 mg/kg &#x02264;2000) (<xref rid="T2" ref-type="table">Table 2</xref>).</p></sec><sec id="s3e"><title>Bioactive Leptin binding affinity:</title><p>From the results of the sections above, we selected six compounds (A8, A9, A10, A11, A14 and A17), which showed the best ADMET
properties and low toxicity to confirm their potential interaction to LepR. A competitive binding assay was conducted. The Bioactive
Leptin ELISA kit (ALPCO) was utilized, employing W100E leptin [<xref rid="R19" ref-type="bibr">19</xref>]. The assay measured the amount
of W100E leptin bound to the immobilized leptin receptor on the kit plate after pre-incubation with each compound. The results
demonstrate that compound A8 discreetly but significantly inhibit W100E leptin binding about 7.89%, while the rest of compounds
exhibited varying degrees of enhanced binding. Notably, compound A9 significantly increased bound leptin by 12.93%
(Figure 2c - see PDF). These findings suggest that the tested compounds possess affinity for the leptin receptor and can modulate the
amount of leptin binding to the receptor.</p></sec><sec id="s4"><title>Discussion:</title><p>In the current study, we searched for compounds with binding affinity to Y472, I503, F504, L505 and L506 residues already reported as
the amino acids that make up the LBD in the leptin receptor. In modern drug discovery, protein-ligand docking plays an important role in
predicting the orientation of the ligand when it is bound to a protein receptor or enzyme using shape and electrostatic interactions to
quantify it. The van der Waals interactions also play an important role, in addition to electrostatic interactions and the formation of
hydrogen bonds. The sum of all these interactions is approximated by a docking score, which represents potentiality of binding
[<xref rid="R23" ref-type="bibr">23</xref>]. The docking was site directed and the amino acids selected as the binding site of the
compounds formed the LBD. However, due to protein folding, several other amino acids can interact with the compounds found and tested,
as shown in <xref rid="T1" ref-type="table">Table 1</xref>, the amino acids that according to docking interact with all compounds are
R615 and L505, with only L505 being part of the LBD, for Y472 an interaction is predicted with 5 of the 18 compounds (A6, A8, A9, A10
and A11), for I503 it is predicted to be an affinity site for 12 of the compounds (A1, A3-A6, A12-18) , with possible less participation,
F504 is predicted to be related to A13 and A16 and for L506 no interactions with the selected compounds are predicted. Natural leptin
has two tryptophan residues (Trp 100 in loop III and Trp 138 at the C terminus of &#x003b1;D). The W100E variant of leptin (pseudo-WT) was
made for crystallization purposes and has since been shown to have similar biological activity to the WT [<xref rid="R24" ref-type="bibr">24</xref>].
In our bioactive leptin assay results, the binding affinity of leptin W100E to its receptor was modified with the 6 compounds tested,
interestingly only compound A8 decreased the amount of leptin detected bound to the receptor suggesting that this compound could be an
antagonist of leptin signaling, while compounds A9, A10, A11, A14 and A17 could act as agonists.</p></sec><sec id="s5"><title>Conclusions:</title><p>Potential modulators of the leptin-LepR interaction were identified using molecular docking. Eighteen compounds exhibiting the lowest
binding free energy (&#x00394;G<sub>binding</sub>) values were selected for further investigation, suggesting a high probability of
interaction with the LepR-LBD. The six compounds demonstrating the most favorable binding poses (A8, A9, A10, A11, A14 and A17) were
evaluated in vitro using ELISA assays to quantify their impact on Leptin-LepR complex formation. Compound A8 demonstrated a notable
reduction in Leptin-LepR interaction by over 7%. Conversely, the remaining five compounds (A9, A10, A11, A14 and A17) enhanced complex
formation, with increases ranging from 2% (A14) to 13% (A9). These findings provide valuable insights into the molecular mechanisms
governing Leptin-LepR interactions and offer potential avenues for the development of novel therapeutic strategies to address leptin
resistance.</p></sec></body><back><fn-group><fn id="FN" fn-type="other"><p>
<bold>Edited by P Kangueane</bold>
</p></fn></fn-group><fn-group><fn id="FN1" fn-type="other"><p><bold>Citation: </bold>Jim&#x000e9;nez-Pineda <italic>et al.</italic> Bioinformation 20(5):404-411(2024)</p></fn></fn-group><fn-group><fn id="FN3" fn-type="other"><p><bold>Declaration on Publication Ethics:</bold> The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/.
The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare
that they are not withholding any information that is misleading to the publisher in regard to this article.</p></fn></fn-group><fn-group><fn id="FN4" fn-type="other"><p><bold>Declaration on official E-mail: </bold> The corresponding author declares that official e-mail from their institution is not available for all authors.</p></fn></fn-group><fn-group><fn id="FN5" fn-type="other"><p><bold>License statement: </bold> This is an Open Access article which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly
credited. This is distributed under the terms of the Creative Commons Attribution License</p></fn></fn-group><fn-group><fn id="FN6" fn-type="other"><p><bold>Comments from readers: </bold> Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to
the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.</p></fn></fn-group><fn-group><fn id="FN7" fn-type="other"><p><bold>Bioinformation Impact Factor:</bold>Impact Factor (Clarivate Inc 2023 release) for BIOINFORMATION is 1.9 with 2,198 citations from 2020 to 2022 taken for IF calculations.</p></fn></fn-group><fn-group><fn id="FN8" fn-type="other"><p><bold>Disclaimer:</bold>The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics
remains neutral and allows authors to specify their address and affiliation details including territory where required. Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical
domain.</p></fn></fn-group><ref-list><title>References</title><ref id="R01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudhakar</surname><given-names>M</given-names></name><etal/></person-group><source>Frontiers in immunology. </source><year>2018</year><volume>9</volume><fpage>1167</fpage><pub-id pub-id-type="pmid">29910808</pub-id>
</element-citation></ref><ref id="R02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceccarini</surname><given-names>G</given-names></name><etal/></person-group><source>Cell metabolism. </source><year>2009</year><volume>10</volume><fpage>148</fpage><pub-id pub-id-type="pmid">19656493</pub-id>
</element-citation></ref><ref id="R03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><etal/></person-group><source>Current diabetes reviews. </source><year>2014</year><volume>10</volume><fpage>131</fpage><pub-id pub-id-type="pmid">24809394</pub-id>
</element-citation></ref><ref id="R04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fei</surname><given-names>H</given-names></name><etal/></person-group><source>Proc Natl Acad Sci USA. </source><year>1997</year><volume>94</volume><fpage>7001</fpage><pub-id pub-id-type="pmid">9192681</pub-id>
</element-citation></ref><ref id="R05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamel</surname><given-names>H.F.M</given-names></name><etal/></person-group><source>Cancer medicine. </source><year>2020</year><volume>9</volume><fpage>5687</fpage><pub-id pub-id-type="pmid">32573960</pub-id>
</element-citation></ref><ref id="R06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iserentant</surname><given-names>H</given-names></name><etal/></person-group><source>Journal of cell science. </source><year>2005</year><volume>118</volume><fpage>2519</fpage><pub-id pub-id-type="pmid">15923664</pub-id>
</element-citation></ref><ref id="R07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peelman</surname><given-names>F</given-names></name><etal/></person-group><source>The Journal of endocrinology. </source><year>2014</year><volume>223</volume><fpage>T9</fpage><pub-id pub-id-type="pmid">25063754</pub-id>
</element-citation></ref><ref id="R08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Hidalgo</surname><given-names>M</given-names></name><etal/></person-group><source> Journal of biomolecular structure &#x00026; dynamics. </source><year>2023</year><volume>41</volume><fpage>2231</fpage><pub-id pub-id-type="pmid">35075977</pub-id>
</element-citation></ref><ref id="R09"><label>9</label><element-citation publication-type="webpage"><comment>
<ext-link xlink:href="https://www.gromacs.org/" ext-link-type="uri">https://www.gromacs.org/</ext-link>
</comment></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="webpage"><comment>
<ext-link xlink:href="https://chembridge.com/" ext-link-type="uri">https://chembridge.com/</ext-link>
</comment></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C.A</given-names></name><etal/></person-group><source>Advanced drug delivery reviews. </source><year>2001</year><volume>46</volume><fpage>3</fpage><pub-id pub-id-type="pmid">11259830</pub-id>
</element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halgren</surname><given-names>T.A</given-names></name></person-group><source>J Comput. Chem. </source><year>1996</year><volume>17</volume><fpage>490</fpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-987X(199604)17:5/6&#x0003c;490::AID-JCC1&#x0003e;3.0.CO;2-P</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wauman</surname><given-names>J</given-names></name><etal/></person-group><source>Frontiers in endocrinology. </source><year>2017</year><volume>8</volume><fpage>30</fpage><pub-id pub-id-type="pmid">28270795</pub-id>
</element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>A.M</given-names></name><name><surname>Labute</surname><given-names>P</given-names></name></person-group><source>Journal of chemical information and modeling. </source><year>2007</year><volume>47</volume><fpage>1933</fpage><pub-id pub-id-type="pmid">17715911</pub-id>
</element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="webpage"><comment>
<ext-link xlink:href="http://www.swissadme.ch" ext-link-type="uri">http://www.swissadme.ch</ext-link>
</comment></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="webpage"><comment>
<ext-link xlink:href="http://lmmd.ecust.edu.cn/admetsar2/" ext-link-type="uri">http://lmmd.ecust.edu.cn/admetsar2/</ext-link>
</comment></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="webpage"><comment>
<ext-link xlink:href="http://admet.scbdd.com/calcpre/index/" ext-link-type="uri">http://admet.scbdd.com/calcpre/index/</ext-link>
</comment></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="webpage"><comment>
<ext-link xlink:href="http://tox.charite.de/protox_II/index.php?site=compound_input" ext-link-type="uri">http://tox.charite.de/protox_II/index.php?site=compound_input</ext-link>
</comment></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chimal-Vega</surname><given-names>B</given-names></name><etal/></person-group><source>American Journal of Agricultural and Biological Science. </source><year>2014</year><volume>9</volume><fpage>430</fpage><pub-id pub-id-type="doi">10.3844/ajabssp.2014.430.438</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallianatou</surname><given-names>T</given-names></name><etal/></person-group><source>Advances in experimental medicine and biology. </source><year>2015</year><volume>822</volume><fpage>187</fpage><pub-id pub-id-type="pmid">25416989</pub-id>
</element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T.T</given-names></name><etal/></person-group><source>Pharmaceutics. </source><year>2021</year><volume>13</volume><fpage>1103</fpage><pub-id pub-id-type="pmid">34371794</pub-id>
</element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>P</given-names></name><etal/></person-group><source>Nucleic acids research. </source><year>2018</year><volume>46</volume><fpage>W257</fpage><pub-id pub-id-type="pmid">29718510</pub-id>
</element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagadala</surname><given-names>N.S</given-names></name><etal/></person-group><source>Biophysical reviews. </source><year>2017</year><volume>9</volume><fpage>91</fpage><pub-id pub-id-type="pmid">28510083</pub-id>
</element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haglund</surname><given-names>E</given-names></name><etal/></person-group><source>The Journal of biological chemistry. </source><year>2018</year><volume>293</volume><fpage>12919</fpage><pub-id pub-id-type="pmid">29950524</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="T1"><label>Table 1</label><caption><title>Chemical details, docking scores and physicochemical properties of 18 selected compounds</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Docking</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>Physicochemical properties</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Compound ID Chembridge Corporation</bold>
</td><td rowspan="1" colspan="1">
<bold>Chemical name</bold>
</td><td rowspan="1" colspan="1">
<bold>Smile code</bold>
</td><td rowspan="1" colspan="1">
<bold>Interacting amino acid residues</bold>
</td><td rowspan="1" colspan="1">
<bold>Least &#x00394;G<sub>binding</sub> (kcal mol-1)</bold>
</td><td rowspan="1" colspan="1">
<bold>Average &#x00394;G<sub>binding</sub> &#x000b1; SD (kcal mol-1)</bold>
</td><td rowspan="1" colspan="1">
<bold>Molecular weight (g mol-1)</bold>
</td><td rowspan="1" colspan="1">
<bold>WLogP</bold>
</td><td rowspan="1" colspan="1">
<bold>LogS</bold>
</td><td rowspan="1" colspan="1">
<bold>tPSA (&#x000c5;<sup>2</sup>)</bold>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">A1. 7788812</td><td rowspan="1" colspan="1">Ethyl 2-{[(3-nitrophenyl) amino] carbonyl} hydrazinecarboxylate</td><td rowspan="1" colspan="1">[N+](=O)([O])C1=CC=CC(=C1)NC(=O)NNC(OCC)=O</td><td rowspan="1" colspan="1">R615, L442, I503, L505, D532, N566</td><td rowspan="1" colspan="1">-12</td><td rowspan="1" colspan="1">-11.02 &#x000b1; 0.40</td><td rowspan="1" colspan="1">268</td><td rowspan="1" colspan="1">1.19</td><td rowspan="1" colspan="1">-2.12</td><td rowspan="1" colspan="1">125.28</td></tr><tr><td rowspan="1" colspan="1">A2. 7790013</td><td rowspan="1" colspan="1">Tert-butyl 2-{[(4-chlorobenzyl) amino] carbonothioyl} hydrazinecarboxylate</td><td rowspan="1" colspan="1">C(NCC1=CC=C(C=C1)Cl)(=S)NNC(=O)OC(C)(C)C</td><td rowspan="1" colspan="1">R615, Y441, L442, L505, D532, F563, P564, N566</td><td rowspan="1" colspan="1">-13.14</td><td rowspan="1" colspan="1">-11.13 &#x000b1; 0.65</td><td rowspan="1" colspan="1">316</td><td rowspan="1" colspan="1">2.59</td><td rowspan="1" colspan="1">-3.38</td><td rowspan="1" colspan="1">94.48</td></tr><tr><td rowspan="1" colspan="1">A3. 9037526</td><td rowspan="1" colspan="1">7-(3,4-dimethoxyphenyl)-2-hydroxy-9 (trifluoromethyl) pyrido [2',3':4,5] thieno[2,3-b] pyridin-4(1H)-one</td><td rowspan="1" colspan="1">C12NC(O)=CC(=O)C=1SC1N=C(C3=CC=C(C(OC)=C3)OC)C=C(C(F)(F)F)C2=1</td><td rowspan="1" colspan="1">T438, L442, T443, Q501, I503, L505, P531, D532, V535, N566, R615</td><td rowspan="1" colspan="1">-14.59</td><td rowspan="1" colspan="1">-11.08 &#x000b1; 1.14</td><td rowspan="1" colspan="1">422</td><td rowspan="1" colspan="1">5.7</td><td rowspan="1" colspan="1">-5.53</td><td rowspan="1" colspan="1">112.68</td></tr><tr><td rowspan="1" colspan="1">A4. 9038033</td><td rowspan="1" colspan="1">9-ethyl-4-hydroxy-7,8,9,10-tetrahydropyrido [2',3':4,5] thieno [2,3-b] quinolin-2(1H)-one</td><td rowspan="1" colspan="1">C12NC(=O)C=C(O)C=1SC1=NC3CCC(CC)CC=3C=C21</td><td rowspan="1" colspan="1">L442, I503, L505, V535, N566, R615</td><td rowspan="1" colspan="1">-14.71</td><td rowspan="1" colspan="1">-11.25 &#x000b1; 1.22</td><td rowspan="1" colspan="1">300</td><td rowspan="1" colspan="1">3.36</td><td rowspan="1" colspan="1">-4.01</td><td rowspan="1" colspan="1">94.22</td></tr><tr><td rowspan="1" colspan="1">A5. 5254870</td><td rowspan="1" colspan="1">4-[4-(benzyloxy) phenyl]-5-[2-(4-methyl-1-piperazinyl) ethyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione</td><td rowspan="1" colspan="1">N(C1=CC=C(C=C1)OCC1C=CC=CC=1)1C(CCN2CCN(CC2)C)=NNC1=S</td><td rowspan="1" colspan="1">D532, L442, T443, Q501, I503, L505, P564, N566, R615</td><td rowspan="1" colspan="1">-13.15</td><td rowspan="1" colspan="1">-11.14 &#x000b1; 0.82</td><td rowspan="1" colspan="1">410</td><td rowspan="1" colspan="1">2.39</td><td rowspan="1" colspan="1">-4.1</td><td rowspan="1" colspan="1">81.41</td></tr><tr><td rowspan="1" colspan="1">A6. 7807483</td><td rowspan="1" colspan="1">N-(2,4-difluorophenyl)-N'-1-naphthyl-1,2-hydrazinedicarbothioamide</td><td rowspan="1" colspan="1">C(=S)(NNC(=S)NC1C=CC(=CC=1F)F)NC1=CC=CC2C=CC=CC1=2</td><td rowspan="1" colspan="1">R615, T438, L442, Y472, I503, L505, P531, D532, G618, L619</td><td rowspan="1" colspan="1">-12.5</td><td rowspan="1" colspan="1">-11.10 &#x000b1; 0.75</td><td rowspan="1" colspan="1">388</td><td rowspan="1" colspan="1">4.76</td><td rowspan="1" colspan="1">-5.06</td><td rowspan="1" colspan="1">112.3</td></tr><tr><td rowspan="1" colspan="1">A7. 5697901</td><td rowspan="1" colspan="1">N-cyclohexyl-2-(3,4,5-trihydroxybenzoyl) hydrazinecarboxamide</td><td rowspan="1" colspan="1">C(O)1=C(O)C=C(C=C1O)C(=O)NNC(=O)NC1CCCCC1</td><td rowspan="1" colspan="1">L442, D532, R615, T438, L505, P531</td><td rowspan="1" colspan="1">-14.95</td><td rowspan="1" colspan="1">-11.41 &#x000b1; 1.03</td><td rowspan="1" colspan="1">309</td><td rowspan="1" colspan="1">1.08</td><td rowspan="1" colspan="1">-2.37</td><td rowspan="1" colspan="1">130.92</td></tr><tr><td rowspan="1" colspan="1">A8. 5803718</td><td rowspan="1" colspan="1">N-{2-[2-(5-isopropyl-2-methylphenoxy) ethoxy]ethyl}-1,2-ethanediamine oxalate</td><td rowspan="1" colspan="1">C1=C(OCCOCCNCCN)C(C)=CC=C1C(C)C</td><td rowspan="1" colspan="1">D532, R615, L442, Y472, L505, S433, P564, N566, G618, L619</td><td rowspan="1" colspan="1">-15.18</td><td rowspan="1" colspan="1">-11.45 &#x000b1; 1.17</td><td rowspan="1" colspan="1">280</td><td rowspan="1" colspan="1">2.06</td><td rowspan="1" colspan="1">-2.32</td><td rowspan="1" colspan="1">56.51</td></tr><tr><td rowspan="1" colspan="1">A9. 5803816</td><td rowspan="1" colspan="1">N-{2-[2-(2-chloro-6-methylphenoxy) ethoxy]ethyl}-1,2-ethanediamine oxalate</td><td rowspan="1" colspan="1">C(OCCOCCNCCN)1=C(C)C=CC=C1Cl</td><td rowspan="1" colspan="1">D532, R615,</td><td rowspan="1" colspan="1">-14.85</td><td rowspan="1" colspan="1">-11.15 &#x000b1; 1.12</td><td rowspan="1" colspan="1">273</td><td rowspan="1" colspan="1">1.59</td><td rowspan="1" colspan="1">-2.05</td><td rowspan="1" colspan="1">56.51</td></tr><tr><td rowspan="1" colspan="1">A10. 5803882</td><td rowspan="1" colspan="1">N-{2-[2-(3-isopropylphenoxy) ethoxy] ethyl}-1,2-ethanediamine oxalate</td><td rowspan="1" colspan="1">C1(=CC=CC(OCCOCCNCCN)=C1)C(C)C</td><td rowspan="1" colspan="1">D532, R615, L442, Y472, L505, P564, N566, R615, G618, L619</td><td rowspan="1" colspan="1">-15.83</td><td rowspan="1" colspan="1">-11.18 &#x000b1; 1.1</td><td rowspan="1" colspan="1">266</td><td rowspan="1" colspan="1">1.75</td><td rowspan="1" colspan="1">-2.01</td><td rowspan="1" colspan="1">56.51</td></tr><tr><td rowspan="1" colspan="1">A11. 5805016</td><td rowspan="1" colspan="1">N-{2-[2-(mesityloxy) ethoxy] ethyl}-1,2-ethanediamine oxalate</td><td rowspan="1" colspan="1">C(OCCOCCNCCN)1C(C)=CC(=CC=1C)C</td><td rowspan="1" colspan="1">D532, R615, Y472, L505, E565, G618, L619</td><td rowspan="1" colspan="1">-14.35</td><td rowspan="1" colspan="1">-11.09 &#x000b1; 1.21</td><td rowspan="1" colspan="1">266</td><td rowspan="1" colspan="1">1.56</td><td rowspan="1" colspan="1">-2.06</td><td rowspan="1" colspan="1">56.51</td></tr><tr><td rowspan="1" colspan="1">A12. 5151565</td><td rowspan="1" colspan="1">3,3'-(1,1-ethanediyl) bis (4-hydroxy-2H-chromen-2-one)</td><td rowspan="1" colspan="1">C(C(C)C1C(=O)OC2=C(C=CC=C2)C=1O)1C(=O)OC2=C(C=CC=C2)C=1O</td><td rowspan="1" colspan="1">R615, T438, L442, I503, L505, P531, D532, V535, N566</td><td rowspan="1" colspan="1">-13.12</td><td rowspan="1" colspan="1">-11.25 &#x000b1; 0.93</td><td rowspan="1" colspan="1">350</td><td rowspan="1" colspan="1">3.46</td><td rowspan="1" colspan="1">-3.75</td><td rowspan="1" colspan="1">100.88</td></tr><tr><td rowspan="1" colspan="1">A13. 5152582</td><td rowspan="1" colspan="1">4,4'-sulfonyldiphthalic acid</td><td rowspan="1" colspan="1">S(=O)(=O)(C1C=CC(=C(C(O)=O)C=1)C(O)=O)C1C=CC(=C(C(O)=O)C=1)C(O)=O</td><td rowspan="1" colspan="1">T438, R615, Y441, L442, I503, F504, L505, P531, F563, P564, N566</td><td rowspan="1" colspan="1">-13.54</td><td rowspan="1" colspan="1">-11.054 &#x000b1; 0.79</td><td rowspan="1" colspan="1">394</td><td rowspan="1" colspan="1">2.39</td><td rowspan="1" colspan="1">-2.73</td><td rowspan="1" colspan="1">191.72</td></tr><tr><td rowspan="1" colspan="1">A14. 9230886</td><td rowspan="1" colspan="1">4-hydroxy-9-methyl-11-phenyl-7,8,9,10-tetrahydropyrido [2',3':4,5] thieno [2,3-b]-1,6-naphthyridin-2(1H)-one</td><td rowspan="1" colspan="1">C12C(C3C=CC=CC=3)=C3CN(C)CCC3=NC=1SC1C(=CC(=O)NC2=1)O</td><td rowspan="1" colspan="1">L442, T438, T443, I503, L505, P531, V535, N566, R615</td><td rowspan="1" colspan="1">-15.63</td><td rowspan="1" colspan="1">-11.14 &#x000b1; 1.05</td><td rowspan="1" colspan="1">363</td><td rowspan="1" colspan="1">2.97</td><td rowspan="1" colspan="1">-4.17</td><td rowspan="1" colspan="1">97.46</td></tr><tr><td rowspan="1" colspan="1">A15. 9237042</td><td rowspan="1" colspan="1">9-ethyl-4-hydroxy-7,8,9,10- tetrahydropyrimido [4',5':4,5] thieno [2,3-b] quinolin-2(1H)-one</td><td rowspan="1" colspan="1">C12C(O)=NC(NC=1C1=C(N=C3C(CC(CC3)CC)=C1)S2)=O</td><td rowspan="1" colspan="1">N566, L442, T443, I503, L505, E565, R615</td><td rowspan="1" colspan="1">-14.18</td><td rowspan="1" colspan="1">-11.41 &#x000b1; 0.97</td><td rowspan="1" colspan="1">301</td><td rowspan="1" colspan="1">2.75</td><td rowspan="1" colspan="1">-4.25</td><td rowspan="1" colspan="1">107.11</td></tr><tr><td rowspan="1" colspan="1">A16. 5301496</td><td rowspan="1" colspan="1">2,2'-[1,2,5-oxadiazole-3,4-diylbis(iminocarbonyl)] dibenzoic acid</td><td rowspan="1" colspan="1">C1(=NON=C1NC(=O)C1=CC=CC=C1C(O)=O)NC(=O)C1=CC=CC=C1C(O)=O</td><td rowspan="1" colspan="1">R615, T438, L442, I503, F504, L505, P531, D532, V535, P564, N566</td><td rowspan="1" colspan="1">-12.56</td><td rowspan="1" colspan="1">-11.44 &#x000b1; 0.61</td><td rowspan="1" colspan="1">396</td><td rowspan="1" colspan="1">1.59</td><td rowspan="1" colspan="1">-2.92</td><td rowspan="1" colspan="1">171.72</td></tr><tr><td rowspan="1" colspan="1">A17. 5190805</td><td rowspan="1" colspan="1">bis(4-hydroxy-2-oxo-2H-chromen-3-yl) acetic acid</td><td rowspan="1" colspan="1">C(C(C(O)=O)C1C(=O)OC2=C(C=CC=C2)C=1O)1C(=O)OC2=C(C=CC=C2)C=1O</td><td rowspan="1" colspan="1">N566, R615, T438, L442, I503, L505, P531, D532, V535, F563, P564</td><td rowspan="1" colspan="1">-15.49</td><td rowspan="1" colspan="1">-12.54 &#x000b1; 0.9</td><td rowspan="1" colspan="1">380</td><td rowspan="1" colspan="1">2.53</td><td rowspan="1" colspan="1">-3.35</td><td rowspan="1" colspan="1">138.18</td></tr><tr><td rowspan="1" colspan="1">A18. 9256439</td><td rowspan="1" colspan="1">9-ethyl-4-hydroxy-11-(trifluoromethyl)-7,8,9,10- tetrahydropyrimido [4',5':4,5] thieno [2,3-b] quinolin-2(1H)-one</td><td rowspan="1" colspan="1">C12C(O)=NC(NC=1C1=C(N=C3C(CC(CC3)CC)=C1C(F)(F)F)S2)=O</td><td rowspan="1" colspan="1">T438, L442, T443, I503, L505, P531, D532, V535, N566, R615</td><td rowspan="1" colspan="1">-14.45</td><td rowspan="1" colspan="1">-12.06 &#x000b1; 0.98</td><td rowspan="1" colspan="1">369</td><td rowspan="1" colspan="1">4.92</td><td rowspan="1" colspan="1">-5.09</td><td rowspan="1" colspan="1">107.11</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><title>ADMET profile of 18 selected compounds.</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Pharmacokinetic properties</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>ID compound Chembridge Corp.</bold>
</td><td rowspan="1" colspan="1">
<bold>D (Distribution)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>M (Metabolism)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>E (Excretion)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>Toxicity</bold>
</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>P-gp substrate</bold>
</td><td rowspan="1" colspan="1">
<bold>Plasma protein binding (PPB) (%)</bold>
</td><td rowspan="1" colspan="1">
<bold>Substrate</bold>
</td><td rowspan="1" colspan="1">
<bold>Inhibitor</bold>
</td><td rowspan="1" colspan="1">
<bold>Half time (T1/2) (h)</bold>
</td><td rowspan="1" colspan="1">
<bold>Renal clearance (CL) (ml/min/kg)</bold>
</td><td rowspan="1" colspan="1">
<bold>LD50 (toxicity class)</bold>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">A1. 7788812</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">54.776</td><td rowspan="1" colspan="1">CYP3A4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.416</td><td rowspan="1" colspan="1">1.525</td><td rowspan="1" colspan="1">11000 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A2. 7790013</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">72.658</td><td rowspan="1" colspan="1">CYP3A4</td><td rowspan="1" colspan="1">CYP2C19</td><td rowspan="1" colspan="1">0.836</td><td rowspan="1" colspan="1">1.457</td><td rowspan="1" colspan="1">630 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A3. 9037526</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">88.8</td><td rowspan="1" colspan="1">CYP3A4</td><td rowspan="1" colspan="1">CYP1A2, CYP2C19, CYP2C9, CYP3A4</td><td rowspan="1" colspan="1">1.852</td><td rowspan="1" colspan="1">1.225</td><td rowspan="1" colspan="1">1000 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A4. 9038033</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">84.161</td><td rowspan="1" colspan="1">CYP3A4, CYP2C9 </td><td rowspan="1" colspan="1">CYP1A2, CYP2C9 </td><td rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">1.338</td><td rowspan="1" colspan="1">1000 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A5. 5254870</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">88.922</td><td rowspan="1" colspan="1">CYP3A4</td><td rowspan="1" colspan="1">CYP1A2, CYP2C19, CYP3A4</td><td rowspan="1" colspan="1">1.758</td><td rowspan="1" colspan="1">1.741</td><td rowspan="1" colspan="1">1000 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A6. 7807483</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">91.41</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">CYP1A2, CYP2C19, CYP2C9</td><td rowspan="1" colspan="1">2.066</td><td rowspan="1" colspan="1">1.011</td><td rowspan="1" colspan="1">2000 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A7. 5697901</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">57.84</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">0.624</td><td rowspan="1" colspan="1">1.458</td><td rowspan="1" colspan="1">2000 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A8. 5803718</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">66.536</td><td rowspan="1" colspan="1">CYPD6</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">1.442</td><td rowspan="1" colspan="1">2.201</td><td rowspan="1" colspan="1">350 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A9. 5803816</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">60.315</td><td rowspan="1" colspan="1">CYP3A4, CYPD6</td><td rowspan="1" colspan="1">CYP1A2, CYP2C19, CYP2D6</td><td rowspan="1" colspan="1">1.157</td><td rowspan="1" colspan="1">1.86</td><td rowspan="1" colspan="1">1750 mg/kg (<sup>4</sup>)</td></tr><tr><td rowspan="1" colspan="1">A10. 5803882</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">63.236</td><td rowspan="1" colspan="1">CYP3A4</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">1.41</td><td rowspan="1" colspan="1">2.255</td><td rowspan="1" colspan="1">610 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A11. 5805016</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">59.496</td><td rowspan="1" colspan="1">CYPD6</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">1.51</td><td rowspan="1" colspan="1">2.283</td><td rowspan="1" colspan="1">350 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A12. 5151565</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">93.146</td><td rowspan="1" colspan="1">CYP2C9</td><td rowspan="1" colspan="1">CYP2C9</td><td rowspan="1" colspan="1">2.022</td><td rowspan="1" colspan="1">1.864</td><td rowspan="1" colspan="1">233 mg/kg <sup>-3</sup></td></tr><tr><td rowspan="1" colspan="1">A13. 5152582</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">79.104</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">1.446</td><td rowspan="1" colspan="1">0.791</td><td rowspan="1" colspan="1">83 mg/kg <sup>-3</sup></td></tr><tr><td rowspan="1" colspan="1">A14. 9230886</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">88.631</td><td rowspan="1" colspan="1">CYP3A4</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">1.951</td><td rowspan="1" colspan="1">1.731</td><td rowspan="1" colspan="1">5000 mg/kg <sup>-5</sup></td></tr><tr><td rowspan="1" colspan="1">A15. 9237042</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">80.207</td><td rowspan="1" colspan="1">CYP3A4</td><td rowspan="1" colspan="1">CYP1A2 CYP2C9</td><td rowspan="1" colspan="1">1.417</td><td rowspan="1" colspan="1">1.347</td><td rowspan="1" colspan="1">1000 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A16. 5301496</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">90.513</td><td rowspan="1" colspan="1">---</td><td rowspan="1" colspan="1">CYP1A2</td><td rowspan="1" colspan="1">1.158</td><td rowspan="1" colspan="1">0.692</td><td rowspan="1" colspan="1">1450 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">A17. 5190805</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">90.997</td><td rowspan="1" colspan="1">CYP2C9</td><td rowspan="1" colspan="1">CYP2C9</td><td rowspan="1" colspan="1">1.788</td><td rowspan="1" colspan="1">1.277</td><td rowspan="1" colspan="1">233 mg/kg <sup>-3</sup></td></tr><tr><td rowspan="1" colspan="1">A18. 9256439</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">85.334</td><td rowspan="1" colspan="1">CYP3A4</td><td rowspan="1" colspan="1">CYP2C9</td><td rowspan="1" colspan="1">1.763</td><td rowspan="1" colspan="1">1.247</td><td rowspan="1" colspan="1">1000 mg/kg <sup>-4</sup></td></tr><tr><td rowspan="1" colspan="1">Median lethal dose (LD50) and toxicity class.</td></tr><tr><td rowspan="1" colspan="1">Class 1 is fatal if swallowed (LD50 &#x02264; 5 mg/kg),</td></tr><tr><td rowspan="1" colspan="1">class 2 fatal if swallowed (LD50 &#x0003e; 5 mg/kg &#x02264; 50),</td></tr><tr><td rowspan="1" colspan="1">class 3 toxic if swallowed (LD50 &#x0003e; 50 mg/kg &#x02264; 300),</td></tr><tr><td rowspan="1" colspan="1">class 4 can be harmful if swallowed (LD50 &#x0003e;300 mg/kg &#x02264; 2000),</td></tr><tr><td rowspan="1" colspan="1">class 5 can be harmful if swallowed (LD50 &#x0003e; 2000 mg/kg &#x02264; 5000)</td></tr><tr><td rowspan="1" colspan="1">and class 6 non-toxic (LD50 &#x0003e; 5000 mg /kg).</td></tr></tbody></table></table-wrap></floats-group></article>